Another PARP-inhibitor in this setting with reasonable toxicity profile and flexibility of efficacy for patients with mutated or non-mutated BRCA status. More options of therapy may decrease cost of treatment in a competitive market.
Practice-changing study for this specific patient population (see inclusion criteria) with approximately 30% risk reduction of death with excellent tolerability of treatment arm of this study.
Very robust improvement of response rate, progression-free survival and decreased risk of death with trastuzumab deruxtecan versus trastuzumab emtansine. Early detection, knowledge about management and pre-treatment risk assessment of pulmonary toxicities are of paramount importance.
Another landmark study supporting the use CDK4/6 drugs along with endocrine therapy in the breast cancer metastatic setting. Missed opportunities insofar as adding CDK 4/6 drugs to endocrine blockade are a concern, since the OS survival difference is significant.
DD-LPS is certainly a disease-process with unmet therapeutic needs. Selinexor versus BSC showed significant PFS improvement. Very interested in validation studies of CALB1 expression and potential combinations with Selinexor.
Importance of NGS testing cannot be overemphasized. Besides poziotinib (which has very reasonable clinical benefit), anti-HER2 combination therapy may be of value in this patient population. Studies are ongoing. Poziotinib-related rash and diarrhea are manageable with proper understanding and interventions.
Another trial corroborating the activity of poziotinib in this setting.
Important guideline update in a very common clinical scenario. Most practitioners prescribe antiresorptive therapy to prevent osteoporosis/osteopenia in the setting of aromatase-therapy inhibitors. Guidelines recommend consideration of bisphosphonate therapy irrespective of endocrine-tumor status.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
